LY3090106 ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
53	シェーグレン症候群	2

53. シェーグレン症候群

臨床試験数 : 305 / 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04563195 (ClinicalTrials.gov)	December 1, 2021	12/9/2020	BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome	BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome	Primary Sjogren's Syndrome	Drug: tibulizumab (LY3090106)	Matthew C. Baker	NULL	Not yet recruiting	18 Years	85 Years	All	12	Phase 2/Phase 3	United States
2	NCT02614716 (ClinicalTrials.gov)	December 10, 2015	24/11/2015	A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)	A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmaco ...	Sjögren's Syndrome	Drug: LY3090106;Drug: Placebo	Eli Lilly and Company	NULL	Completed	18 Years	65 Years	All	32	Phase 1	United States;Bulgaria;Georgia;Romania

First Previous1Next Last